PACB

PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.

Pacific Biosciences of California (PACB) closed the most recent trading day at $1.66, moving 1.19% from the previous trading session.

Pacific Biosciences of California (PACB) closed at $1.68 in the latest trading session, marking a -2.89% move from the prior day.

PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.

New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight

MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies' Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.

PacBio teams with Blank Bio after its $7.2M seed round, using HiFi long reads to build RNA AI models from patient tumor samples.

SAN FRANCISCO--(BUSINESS WIRE)--Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology.